Claims for Patent: 12,458,632

Summary for Patent: 12,458,632

Title:	Treatment of migraine
Abstract:	The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
Inventor(s):	Mary Ann Johnson, Leonardo R. Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
Assignee:	Merck Sharp and Dohme LLC
Application Number:	US19/042,453
Patent Claims:	1. A rapid-release pharmaceutical tablet comprising: (i) an amorphous compound of formula Ia: wherein each of Rb is hydrogen, and (ii) a disintegration system, wherein when said tablet is subjected to a dissolution test complying with USP 30 NF25 Chapt. 711, said tablet releases at least about 90% of the compound of Formula Ia contained therein in less than about 20 minutes. 2. The tablet according to claim 1, wherein the tablet comprises an amorphous dispersion of the compound of formula Ia. 3. The tablet according to claim 2, wherein the dispersion comprises a polymer matrix. 4. The tablet according to claim 3, wherein the polymer matrix comprises an excipient selected from polyvinylpyrrolidone-vinyl acetate copolymer and HPMCAS. 5. The tablet according to claim 3, wherein the dispersion comprises a dispersing agent. 6. The tablet according to claim 1, wherein the disintegration system comprises a disintegrant selected from croscarmellose sodium and crospovidone. 7. The tablet according to claim 1, wherein the disintegration system comprises sodium chloride. 8. The tablet according to claim 3, wherein the disintegration system comprises croscarmellose sodium and sodium chloride. 9. The tablet according to claim 4, wherein the disintegration system comprises croscarmellose sodium and sodium chloride. 10. The tablet according to claim 1, wherein the tablet further comprises at least one additional excipient selected from a diluent, a glidant, and a lubricant. 11. The tablet according to claim 1, wherein the tablet comprises at least one additional excipient selected from mannitol, colloidal silica, microcrystalline cellulose, and sodium stearyl fumarate. 12. The tablet according to claim 1, wherein the tablet achieves complete disintegration in less than about 22 minutes in a tablet disintegration test complying with USP31-NF26 Chapt. 701. 13. The tablet according to claim 1, wherein the tablet comprises about 50 mg of the compound of formula Ia. 14. A rapid-release pharmaceutical tablet comprising: (i) an amorphous compound of formula Ia: wherein each of Rb is hydrogen, and (ii) a disintegrant, wherein when said tablet is subjected to a dissolution test complying with USP 30 NF25 Chapt. 711, said tablet releases at least about 90% of the compound of Formula Ia contained therein in less than about 20 minutes. 15. The tablet according to claim 14, wherein the tablet comprises an amorphous dispersion of the compound of Formula Ia. 16. The tablet according to claim 14, wherein the tablet comprises a salt. 17. The tablet according to claim 16, wherein the salt is sodium chloride. 18. The tablet according to claim 14, wherein the disintegrant is selected from the group consisting of croscarmellose sodium and crospovidone. 19. The tablet according to claim 15, wherein (i) the dispersion comprises a polymer matrix, (ii) the disintegrant is selected from the group consisting of croscarmellose sodium and crospovidone, and (iii) the tablet further comprises sodium chloride. 20. The tablet according to claim 14, wherein the tablet achieves complete disintegration in less than about 22 minutes in a tablet disintegration test complying with USP31-NF26 Chapt. 701. 21. The tablet according to claim 14, wherein the tablet comprises about 50 mg of the compound of formula Ia. 22. The tablet according to claim 1, wherein the dissolution test is conducted in a paddle-stirring apparatus equipped with USP2 paddles. 23. The tablet according to claim 22, wherein the paddle-stirring apparatus is operated at 50 rpm. 24. The tablet according to claim 22, wherein the dissolution test is conducted in 900 ml of simulated gastric fluid at pH 1.8 at 37° C. 25. The tablet according to claim 1, wherein the dissolution test is conducted in 900 ml of simulated gastric fluid at pH 1.8 at 37° C. 26. The tablet according to claim 14, wherein the dissolution test is conducted in a paddle-stirring apparatus equipped with USP2 paddles. 27. The tablet according to claim 26, wherein the paddle-stirring apparatus is operated at 50 rpm. 28. The tablet according to claim 26, wherein the dissolution test is conducted in 900 ml of simulated gastric fluid at pH 1.8 at 37° C. 29. The tablet according to claim 14, wherein the dissolution test is conducted in 900 ml of simulated gastric fluid at pH 1.8 at 37° C.